Comparative Pharmacology
Head-to-head clinical analysis: CYKLOKAPRON versus HEMADY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYKLOKAPRON versus HEMADY.
CYKLOKAPRON vs HEMADY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
HEMADY is a phytonadione (vitamin K1) formulation that promotes hepatic synthesis of clotting factors II, VII, IX, and X, reversing anticoagulation by inhibiting vitamin K epoxide reductase.
1 g (10 mL) IV over 5-10 minutes every 6-8 hours; or 25-50 mg/kg/day IV divided every 6-8 hours. Oral: 1-1.5 g 3-4 times daily.
Adult: 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours (renal impairment extends to 10-20 hours).
Terminal elimination half-life is 1.2-2 hours in healthy adults; clinically relevant as it requires frequent dosing (every 4-6 hours) for sustained effect.
Renal: >95% as unchanged drug via glomerular filtration; minimal biliary/fecal (<5%).
Primarily renal excretion of unchanged drug (70-80%), with 20-30% metabolized and excreted as inactive metabolites in urine; less than 5% eliminated in feces via biliary secretion.
Category C
Category C
Antifibrinolytic
Antifibrinolytic